PASG Stock Overview
Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Passage Bio, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.22 |
| 52 Week High | US$1.79 |
| 52 Week Low | US$0.58 |
| Beta | 1.29 |
| 1 Month Change | -3.94% |
| 3 Month Change | 25.77% |
| 1 Year Change | 18.45% |
| 3 Year Change | -93.73% |
| 5 Year Change | n/a |
| Change since IPO | -94.50% |
Recent News & Updates
Recent updates
We're Keeping An Eye On Passage Bio's (NASDAQ:PASG) Cash Burn Rate
Feb 27
Is Passage Bio (NASDAQ:PASG) In A Good Position To Deliver On Growth Plans?
Nov 13We Think Passage Bio (NASDAQ:PASG) Needs To Drive Business Growth Carefully
Jun 23Is Passage Bio (NASDAQ:PASG) In A Good Position To Deliver On Growth Plans?
Nov 13Passage appoints William Chou CEO
Oct 10Passage Bio GAAP EPS of -$0.73 beats by $0.09
Aug 04We're A Little Worried About Passage Bio's (NASDAQ:PASG) Cash Burn Rate
Jun 03Passage Bio: Worth Keeping An Eye On
Apr 11Will Passage Bio (NASDAQ:PASG) Spend Its Cash Wisely?
Dec 15Passage Bio (NASDAQ:PASG) Is In A Good Position To Deliver On Growth Plans
Aug 19Passage Bio: Price Reduced, But Without Data, Does Not Look Convincing
Jun 06Passage Bio partners with InformedDNA to offer counseling, testing for early dementia
May 03We're Hopeful That Passage Bio (NASDAQ:PASG) Will Use Its Cash Wisely
Mar 08Do Institutions Own Passage Bio, Inc. (NASDAQ:PASG) Shares?
Feb 01
Passage Bio on go with PBGM01 gene therapy trial in the U.S.
Jan 04Need To Know: Passage Bio, Inc. (NASDAQ:PASG) Insiders Have Been Buying Shares
Dec 28U.K. authorizes Passage Bio's PBGM01 trial
Dec 10Passage Bio (PASG) Investor Presentation - Slideshow
Nov 16Passage Bio EPS beats by $0.13
Nov 10Passage Bio’s PBKR03 nabs Orphan drug tag and accelerated review status for Krabbe disease
Oct 28Shareholder Returns
| PASG | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 1.7% | 0.4% | 1.0% |
| 1Y | 18.4% | 0.9% | 21.9% |
Return vs Industry: PASG exceeded the US Biotechs industry which returned 0.7% over the past year.
Return vs Market: PASG underperformed the US Market which returned 24.9% over the past year.
Price Volatility
| PASG volatility | |
|---|---|
| PASG Average Weekly Movement | 14.6% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: PASG's share price has been volatile over the past 3 months.
Volatility Over Time: PASG's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 58 | Will Chou | www.passagebio.com |
Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other program for huntington’s disease.
Passage Bio, Inc. Fundamentals Summary
| PASG fundamental statistics | |
|---|---|
| Market cap | US$75.17m |
| Earnings (TTM) | -US$102.06m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.7x
P/E RatioIs PASG overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PASG income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$102.06m |
| Earnings | -US$102.06m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.66 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did PASG perform over the long term?
See historical performance and comparison